News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Elvina Almuradova: How GEMSTONE-303 differs from other trials
Elvina Almuradova/LinkedIn
Feb 26, 2025, 10:59

Elvina Almuradova: How GEMSTONE-303 differs from other trials

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared an article by Xiaotian Zhang, et al. on LinkedIn:

“GEMSTONE-303 Study.

The GEMSTONE-303 trial investigated whether the addition of sugemalimab (an anti–PD-L1 monoclonal antibody) to capecitabine plus oxaliplatin (CAPOX) improves progression-free survival (PFS) and overall survival (OS) in advanced gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5.

  • Overall survival (OS): 15.6 months vs. 12.6 months (HR: 0.75; P = 0.006).
  • In PD-L1 CPS ≥10 patients: OS improved to 17.8 months vs. 12.5 months (HR: 0.64; P = 0.002).
  • Progression-free survival (PFS): 7.6 months vs. 6.1 months (HR: 0.66; P < 0.001).
  • Objective response rate (ORR) in PD-L1 CPS ≥5 patients: 68.6%, the highest among phase 3 trials.

How GEMSTONE-303 Differs from Other Trials:

  • Selective Patient Population: Included only PD-L1 CPS ≥5 patients.
  • Chemotherapy Regimen: Used CAPOX exclusively, unlike other trials that included FOLFOX or other IV-based regimens.
  • Study Location: Conducted at 54 sites in China, enrolling 90% gastric cancer patients.
  • Lower Rate of Peritoneal Metastases: 13% vs. 20–44% in other trials.
  • No Maintenance Chemotherapy: Treatment stopped after 6 cycles, except for sugemalimab or placebo.
  • Microsatellite Instability (MSI) Status Not Reported, despite its known impact on immunotherapy response.”

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.

Authors: Xiaotian Zhang, et al.

Elvina Almuradova: How GEMSTONE-303 differs from other trials

Adenocarcinoma cancer capecitabine chemotherapy Elvina Almuradova European Institute of Oncology fight against cancer FOLFOX gastric cancer GEMSTONE-303 Global fight against cancer IEO immunotherapy OncoDaily Oncology oxaliplatin Peritoneal Metastases sugemalimab
Special Coverage
Blog
Feb 26, 2025, 10:59
Wafaa Rashed: Enhancing Public Awareness and Education of Genomic Research in Ghana
Science
Feb 26, 2025, 10:59
Elvina Almuradova: How GEMSTONE-303 differs from other trials
Oncolibrary
Feb 26, 2025, 10:54
New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Insight
Feb 26, 2025, 10:54
Pietro De Placido: The SURVIVE Study will challenge the "no symptoms, no scan" BC surveillance model
Insight
Feb 26, 2025, 10:50
Jarushka Naidoo: Mucinous lung adenocarcinomas - clinical features and outcomes
Blog
Feb 26, 2025, 10:49
Rizwan Jafri: Our annual Colon Cancer Awareness 5K event
Societies
Feb 26, 2025, 10:39
ESMO Guidelines Slideset on Metastatic Colorectal Cancer
Blog
Feb 26, 2025, 10:32
Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling
Blog
Feb 26, 2025, 10:25
New Approaches Towards T Cell Receptor Engineered Cancer Immunotherapies - AACR
Career
Feb 26, 2025, 10:12
Bruna Pellini: Honored to receive the Junior Faculty Research Award for Clinical Science
Blog
Feb 26, 2025, 10:09
No evidence to suggest that CAR T cell therapy leads to secondary cancers
Science
Feb 26, 2025, 10:06
Myeloma Paper of the Day, February 26th, suggested by Robert Orlowski